Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Emerging Treatments in SCLC: Targeting DNA Damage

August 19th 2021

Thoracic oncology expert Vivek Subbiah, MD, provides an overview of recent clinical trials studying agents targeting DNA damage for the treatment of small cell lung cancer.

Preferred Treatment for ALK-Rearranged NSCLC

August 19th 2021

Experts have a discussion about their preferred treatment approach for newly diagnosed ALK-rearranged non–small cell lung cancer (NSCLC).

Mobocertinib’s Safety Profile

August 19th 2021

Recommendations for mitigating and managing common treatment-related adverse events associated with mobocertinib and other tyrosine kinase inhibitors.

Biomarkers for Immunotherapy in Resectable NSCLC

August 18th 2021

Dr Roy S. Herbst comments on the utilization of biomarkers and information needed to help aid in treatment decisions about perioperative therapy for patients with resectable non–small cell lung cancer.

PD-1/Chemo Combos Raise the Stakes in SCLC, as Focus Shifts to Leveraging Molecular Testing

August 18th 2021

Jonathan W. Goldman, MD, discusses the significance of the phase 3 CASPIAN and IMpower133 trials in small cell lung cancer and efforts made to optimize molecular testing.

Atezolizumab After Adjuvant Chemotherapy in Resectable NSCLC

August 18th 2021

Dr Martin Dietrich comments on the IMpower010 trial of atezolizumab versus best supportive care after adjuvant chemotherapy in patients with resected non–small cell lung cancer.

Dr. Skoulidis on the Rationale to Target TROP2 in Lung Cancer

August 17th 2021

Ferdinandos Skoulidis, MD, PhD, MRCP, discusses the rationale to target TROP-2 in lung cancer.

Dr. Schenk on the Importance of Investigating Novel Targets in Lung Cancer

August 17th 2021

Erin Schenk, MD, PhD, discusses the importance of investigating novel targets and pathways in lung cancer.

Dr. Santos on the Potential Role for CEACAM5- and KEAP1-Targeted Therapies in NSCLC

August 17th 2021

Edgardo S. Santos, MD, discusses the potential role for CEACAM5- and KEAP1-targeted therapies in non–small cell lung cancer.

Chachoua on Leveraging Screening Opportunities in Lung Cancer

August 16th 2021

Dr. Chachoua discusses key guidelines for lung cancer screening, the psychological and financial implications of screening, and the opportunities of a screening initiative instated by NYU Langone Health.

ALK-Rearranged NSCLC: Updates From ASCO

August 12th 2021

A summary of recent data that were presented at the American Society of Clinical Oncology (ASCO) 2021 annual meeting for ALK-rearranged non–small cell lung cancer (NSCLC).

EGFR Tyrosine Kinase Inhibitors and Brain Metastases

August 12th 2021

Commentary on the use of EGFR tyrosine kinase inhibitors and their efficacy on non–small cell lung cancer brain metastases.

EGFR Exon 20–Directed Therapy With Mobocertinib

August 12th 2021

Potential implications for treating patients with metastatic non–small cell lung cancers with EGFR exon 20 insertion mutations with mobocertinib, based on the EXCLAIM cohort.

Non–small Cell Lung Cancer With EGFR Exon 20 Insertion

August 12th 2021

Rare drivers such as EGFR exon 20 insertions and what they mean for treatment of patients with metastatic non–small cell lung cancer.

Emerging Treatments in SCLC: Bispecific Antibodies

August 12th 2021

Expert panelists weigh in on emerging data from recent presentations on small cell lung cancer, including novel immunotherapy approaches such as bispecific antibodies targeting DLL3 or therapies targeting TIGIT.

RET-Fusions in NSCLC: Updates From ASCO

August 12th 2021

An overview of the RET-fusion data updates that were presented at the American Society of Clinical Oncology (ASCO) 2021 annual meeting in non–small cell lung cancer (NSCLC).

Targeted Therapy for Metastatic Non–small Cell Lung Cancer

August 12th 2021

Mark A. Socinski, MD shares a brief overview of the biomarkers and FDA-approved targeted therapies for non–small cell lung cancers.

SCLC: Rechallenging With Chemotherapy + I/O

August 12th 2021

Anne Chiang, MD, PhD, renowned expert in thoracic oncology, guides a discussion on whether to rechallenge with chemotherapy + I/O after progression of small cell lung cancer.

Clinical Endpoints and Neoadjuvant Therapy for Resectable NSCLC

August 11th 2021

The impact of endpoints used in clinical trials of neoadjuvant therapy for resectable non–small cell lung cancer as they relate to newer drug approvals and real-world practice.

Neoadjuvant Immunotherapy for Resectable NSCLC

August 11th 2021

Martin Dietrich, MD, PhD, describes his interpretations of the KEYNOTE-799 study of pembrolizumab plus chemoradiation therapy for unresectable stage III non–small cell lung cancer.